Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$8.12 -1.2%	$7.12	$5.47 ▼ $11.99	$166.23M	N/A	83,328 shs	43,371 shs
GLSI Greenwich LifeSciences	$12.17 +0.7%	$10.56	$8.06 ▼ $16.50	$162.69M	1.65	61,385 shs	19,800 shs
HYPD Hyperion DeFi	$7.20 +7.6%	$9.03	$0.85 ▼ $75.18	$41.00M	2.42	717,261 shs	304,548 shs
TVGN Tevogen Bio	$0.95 -3.2%	$1.14	$0.26 ▼ $3.09	$174.39M	-0.77	1.64 million shs	733,718 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	+1.25%	+29.71%	-23.03%	-11.26%
GLSI Greenwich LifeSciences	0.00%	-0.08%	-1.06%	+24.95%	-6.31%
HYPD Hyperion DeFi	0.00%	-3.49%	-54.60%	+537.17%	-88.22%
TVGN Tevogen Bio	0.00%	+5.31%	-23.52%	-16.08%	+30.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	2.2662 of 5 stars	3.5	0.0	1.6	3.3	0.0
GLSI Greenwich LifeSciences	1.3741 of 5 stars	3.5	0.0	1.8	1.7	0.0
HYPD Hyperion DeFi	0.3634 of 5 stars	1.0	0.0	2.5	0.8	0.6
TVGN Tevogen Bio	3.7634 of 5 stars	3.5	3.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	152.46% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	220.46% Upside
HYPD Hyperion DeFi	2.00	Hold	$2.00	-72.22% Downside
TVGN Tevogen Bio	3.00	Buy	$10.00	954.52% Upside

Current Analyst Ratings Breakdown

Latest HYPD, TVGN, ACTU, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
HYPD Hyperion DeFi	$44.44K	922.72	N/A	N/A	$6.56 per share	1.10
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	-19,736.59%	-263.86%	N/A
GLSI Greenwich LifeSciences	-$15.79M	-$1.36	N/A	N/A	N/A	N/A	-611.35%	-426.01%	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	-876.25%	-181.67%	N/A
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	N/A

Latest HYPD, TVGN, ACTU, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACTU Actuate Therapeutics	-$0.19	-$0.30	-$0.11	-$0.30	N/A	N/A
8/14/2025	Q2 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.30	-$0.06	-$0.30	N/A	N/A
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.46	0.46
GLSI Greenwich LifeSciences	N/A	1.91	1.91
HYPD Hyperion DeFi	0.20	0.91	0.34
TVGN Tevogen Bio	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
GLSI Greenwich LifeSciences	4.16%
HYPD Hyperion DeFi	25.84%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
GLSI Greenwich LifeSciences	51.67%
HYPD Hyperion DeFi	10.86%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	20.47 million	6.28 million	N/A
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
HYPD Hyperion DeFi	40	5.70 million	5.08 million	No Data
TVGN Tevogen Bio	3	183.89 million	49.21 million	N/A

HYPD, TVGN, ACTU, and GLSI Headlines

Recent News About These Companies

Semper Paratus Acquisition (NASDAQ:TVGN) Stock Price Down 3% - Here's What Happened

August 16 at 3:56 AM | marketbeat.com

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

August 14 at 3:55 PM | globenewswire.com

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 13, 2025 | globenewswire.com

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

August 11, 2025 | globenewswire.com

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

August 11, 2025 | globenewswire.com

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

August 11, 2025 | globenewswire.com

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

August 11, 2025 | globenewswire.com

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

August 8, 2025 | globenewswire.com

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

August 7, 2025 | globenewswire.com

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

August 6, 2025 | globenewswire.com

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 5, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital

August 5, 2025 | marketbeat.com

Semper Paratus Acquisition Corporation (NASDAQ:TVGN) Sees Significant Increase in Short Interest

August 2, 2025 | marketbeat.com

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

August 1, 2025 | globenewswire.com

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

August 1, 2025 | globenewswire.com

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

July 30, 2025 | globenewswire.com

Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

July 28, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.7% - Should You Sell?

July 24, 2025 | marketbeat.com

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

July 18, 2025 | globenewswire.com

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

July 17, 2025 | globenewswire.com

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

July 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HYPD, TVGN, ACTU, and GLSI Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$8.12 -0.10 (-1.22%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.13 +0.01 (+0.12%)

As of 08/15/2025 05:02 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Greenwich LifeSciences NASDAQ:GLSI

$12.17 +0.09 (+0.75%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$11.92 -0.24 (-2.01%)

As of 08/15/2025 07:26 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Hyperion DeFi NASDAQ:HYPD

$7.20 +0.51 (+7.62%)

As of 08/15/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Tevogen Bio NASDAQ:TVGN

$0.95 -0.03 (-3.23%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.00 (+0.07%)

As of 08/15/2025 07:59 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time